• In May 2026, Indivior Pharmaceuticals reported two real-world evidence studies showing that adherence to its monthly injectable buprenorphine, SUBLOCADE, was associated with substantially lower relapse risk, fewer serious infections, and reduced healthcare utilization in people with opioid use disorder.
• Because these analyses linked SUBLOCADE use to both clinical and healthcare resource benefits, they may strengthen the drug’s appeal to clinicians, payers, and treatment programs seeking more effective long-term OUD management.
• We’ll now examine how these real-world SUBLOCADE adherence benefits might influence Indivior’s existing investment narrative and long-acting OUD focus.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior, you need to believe that long acting injectables become a core option in opioid use disorder treatment and that SUBLOCADE remains a leading choice. The new real world data on relapse and healthcare use reinforces Indivior’s focus on long acting OUD therapy, but does not by itself remove the key near term risk that long acting injectable penetration and SUBOXONE Film resilience could fall short of expectations.

The most relevant recent announcement is Indivior’s Q1 2026 update, where the company raised full year revenue guidance to US$1,215 million to US$1,285 million, supported by SUBLOCADE. The latest adherence data may give additional clinical context to that outlook, particularly for investors watching how label updates, direct to consumer efforts, and payer relationships convert into sustained SUBLOCADE use in real world settings.

Yet, against this encouraging evidence, investors should still recognize the risk that long acting injectable adoption in OUD could stall well below levels seen in other chronic conditions...

Indivior Pharmaceuticals' narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and an earnings increase of about $353.5 million from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, in line with its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenues of about US$1.3 billion and earnings near US$596 million by 2029, so if you think SUBLOCADE’s real world advantages will meaningfully lift long acting injectable penetration compared with the risk that adoption stalls, you may see their view as far more optimistic than the consensus.

Explore 4 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.